# Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection)

> **NCT06744686** · PHASE1 · COMPLETED · sponsor: **Suzhou HepaThera Biotech Co., Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** HT-102
- **DRUG:** HT-102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06744686
- **Lead sponsor:** Suzhou HepaThera Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-12
- **Primary completion:** 2024-03-12
- **Final completion:** 2024-06-18
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06744686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06744686, "Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06744686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*